FASN-IN-3 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A.
IC50&Target
FASN
体外研究
Human PBMC and monocytes in cell cultures are stimulated with lipopolysaccharide (LPS), a Toll 4 receptor agonist, or lipoteichoic acid (LTA), a Toll 2 receptor agonist. Stimulation with either LPS or LTA plus DMSO, the solvent for FASN-IN-3 (Compound 242A), results in secretion of IL-1 beta. FASN inhibitor 1 treatment of PBMC, which is a mixed population of mononuclear cells including both lymphocytes and monocytes, reduces the level of IL-1 beta resulting from either LPS or LTA stimulation. For monocytes, FASN-IN-3 treatment reduces the level of IL-1 beta resulting from LTA stimulation whereas there is only a slight reduction after LPS stimulation.
分子量
384.47
CAS号
2097262-60-5
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder
-20°C
3 years
4°C
2 years
In solvent
-80°C
6 months
-20°C
1 month
溶解性数据
In Vitro:
DMSO : 33.33 mg/mL (86.69 mM; ultrasonic and warming and heat to 80°C)